Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

nce as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

About Prima BioMedPrima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

Clinical AppendixStudy Title CAN-004: A Randomized, Double-Blinded, Placebo-Controlled Phase 2/3 Trial of CVac™ (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) Following Optimal Debulking Surgery and First-line Chemotherapy

Study DesignThis is a randomized, double-blinded, placebo-controlled Phase 2/3 trial of CVac as maintenance treatment in patients with EOC following optimal debulking surgery and first-line chemotherapy. The initial planned enrollment is 750 patients. The primary analysis of irPFS is planned to be conducted after 350 irPFS events (confirmed immune-related progressive disease [irPD] or death) have occurred. The primary analysis for OS is planned to be
'/>"/>

SOURCE Prima BioMed Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... , Aug. 31, 2015  Ascendant Solutions, Inc. ... today announced that its Healthcare subsidiary, Dougherty,s Holdings, has ... on the downtown square of Springtown, Texas ... than 35 years, this community-based pharmacy has provided retail ... of Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
... grounds, direct programming is superior,to cloning as a ... Nov. 20 Two major scientific,papers published this ... way to,generate patient-matched human pluripotent stem cells without ... or human or animal eggs.,Research groups in Wisconsin ...
... 20 The following statement,was released today by ... the Elizabeth Glaser Pediatric AIDS Foundation:, "Four ... Relief,(PEPFAR) began funding treatment and prevention, today,s report ... remains a devastating worldwide,pandemic, we are beginning to ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need 2
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... and stickers to keep little ones' safety top of mind at all times. , ... particular focus. According to the JPMA's Baby Safety Zone website, this year's theme is ...
(Date:8/31/2015)... ... ... The PT Outcomes Registry is an organized system for collecting data to evaluate ... being developed by the American Physical Therapy Association (APTA). , Al Amato, PT, MBA, ... FOTO Outcomes measures as one of the primary global outcomes measures to be used ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... a wealth of information for specific translation services within the medical and pharmaceutical ... incredible track record of successful work. , ITC Global Translations specializes in professional ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... insurance, announced today their new “ InstantQuote ” tool, which summarizes all available ... easy-to-understand format. The technology tool is designed to help India Network members make ...
(Date:8/31/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... August 31, ... ... has launched pre and postnatal fitness classes. , Starting September 1st ... classes are called "The Mom Bod" and "Healthy Body, Healthy Baby." , More ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... early-stage breast cancer that had spread to a nearby lymph ... therapy, women who just had the sentinel lymph node removed ... spread from the primary tumor) did not have worse survival ... (surgery to remove lymph nodes found in the armpit), according ...
... -- Researchers at the University at Buffalo have devised ... these medically important molecules from losing their shape and ... help speed the development of peptide-based drugs against diseases ... are simpler than existing techniques, one of which employs ...
... HealthDay Reporter , TUESDAY, Feb. 7 (HealthDay News) -- ... new "universal" influenza vaccine: one that might be effective against all ... as now happens. "Our hope is to develop a vaccine ... so we won,t need to keep making new flu vaccines each ...
... researchers from the University of California, San Diego School ... two distinct neuronal signaling pathways activated by a topical ... One pathway produces the therapeutic benefit; the other induces ... published in this week,s early online edition of the ...
... , TUESDAY, Feb. 8 (HealthDay News) -- In pregnant women, ... significantly higher blood pressure, new research suggests. The study ... had a lead level higher than about 1 microgram per ... lower than the safety thresholds set by the U.S Centers ...
... TUCSON, Ariz., Feb. 8, 2011 The Muscular Dystrophy ... support new research to advance understanding of disease processes ... ALS and other related neuromuscular diseases affecting more than ... made possible by generous public support of the MDA ...
Cached Medicine News:Health News:Limited lymph node removal for certain breast cancer does not appear to result in poorer survival 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:'Universal' Flu Vaccine Shows Promise in Early Trial 2Health News:'Universal' Flu Vaccine Shows Promise in Early Trial 3Health News:The hitch in the drug? The itch in the drug 2Health News:Lead Exposure May Raise Blood Pressure in Pregnancy 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Children's hospital hand drill, hexagonal handle, twist drill diameter 4.2 mm....
Hudson Drill hand drill....
Hudson Downs hand drill....
Medicine Products: